Herpes zoster infection and statins: which implications in clinical practice?
| Autor: | Claudio Bilato, Loris Roncon, Marco Zuin, Giovanni Zuliani, Gianluca Rigatelli, Roberto L’Erario |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Adult
Risk 0301 basic medicine Microbiology (medical) medicine.medical_specialty Statin medicine.drug_class viruses 030106 microbiology medicine.disease_cause Herpes Zoster 03 medical and health sciences 0302 clinical medicine Medical microbiology Internal medicine Epidemiology medicine Humans Immunologic Factors Herpes zoster infection 030212 general & internal medicine business.industry Public health Varicella zoster virus virus diseases General Medicine Middle Aged Clinical Practice Infectious Diseases Relative risk Hydroxymethylglutaryl-CoA Reductase Inhibitors business |
| Zdroj: | European Journal of Clinical Microbiology & Infectious Diseases. 38:93-99 |
| ISSN: | 1435-4373 0934-9723 |
| Popis: | Herpes zoster (HZ), which is caused by reactivation of latent varicella zoster virus (VZV), constitutes a major public health concern in both short- and long-term periods. Over the last years, several epidemiological studies have demonstrated that statin use is associated with increased risk of HZ at cerebral level. Because statins are among the most popular and best-selling drugs in western countries, this potential negative pleiotropic effect could have important implications in the daily clinical practice. In the present manuscript, we reviewed the available data on the statin use and the relative risk of HZ infection. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink